Purpose: To describe cases presenting with features of idiopathic macular telangiectasia (MacTel) Type 2 and central serous chorioretinopathy (CSC).
C entral serous chorioretinopathy (CSC) is characterized by serous retinal detachments that often spontaneously resolve, [1] [2] [3] [4] and most commonly affects middle-aged men. 5 This disorder is associated with choroidal vascular dilation and multifocal hyperpermeability, thickening of the choroid, alterations of the retinal pigment epithelium, and leakage into the subretinal space. It may be triggered by environmental factors such as psychological stress, [6] [7] [8] [9] corticosteroid intake, 5, 10, 11 or circadian rhythm dysregulation. 12, 13 Predisposing factors possibly linked to genetic traits include increased choroidal thickness, [14] [15] [16] cardiovascular risk, 5, 10, 11, 17 psychiatric illness, 5, [18] [19] [20] [21] and allergy. 10, 11 Genetic variants associated with CSC have been identified in the complement factor H, 22, 23 agerelated maculopathy susceptibility-2 23 and cadherin-5 genes. 24 Type 2 idiopathic macular telangiectasia (MacTel Type 2) is a macular disease manifesting with subtle leakage from perifoveal retinal telangiectasia, [25] [26] [27] [28] [29] [30] macular pigment loss, 31, 32 intraretinal cavitations, crystalline deposits, focal disruption of the retinal layers, 33, 34 or photoreceptor loss. 35, 36 First symptoms usually occur in the fifth and sixth decades, 37 and MacTel Type 2 is frequently associated with diabetes mellitus, hypertension or cardiovascular disease. 38 Despite reports of familial cases, 39, 40 no Mendelian inheritance pattern has been evidenced. 41, 42 Recently, genome-wide analysis identified variants in the glycine/serine metabolic pathway. 43 Müller cell loss has been observed in MacTel Type 2 eyes 44, 45 and in two proposed rodent models recapitulating part of MacTel Type 2 phenotype. 46, 47 Although the role of Müller cells in MacTel Type 2 is not well understood, it is considered a neurodegenerative disease with secondary vascular changes.
There is one previous report of an atypical copresentation of CSC and MacTel Type 2, but there is no study focusing on a possible overlap between both disorders and the frequency. 48 We report herein a series of cases combining CSC and MacTel Type 2 features.
Methods
This observational, multicenter, retrospective case series involving human subjects was designed in accordance with the Tenets of the Declaration of Helsinki. It was approved by the Western Institutional Review Board (Puyallup, WA), the Combined NeuroScience Institutional Review Board at the National Institutes of Health (Bethesda, MD), the Swiss Federal Department of Health Ethics Committee (Lausanne, Switzerland, CER-VD no. 19/15), and the Rotterdam Eye Hospital Review Board (Rotterdam, The Netherlands).
Clinical databases of four retina tertiary centers were searched for codiagnoses of MacTel Type 2 and CSC, after one patient was diagnosed with both diseases at Jules-Gonin Eye Hospital, Lausanne, Switzerland (F.B.-C.). Optical coherence tomography (OCT) was performed on Spectralis (Heidelberg Engineering, Heidelberg, Germany), Cirrus (Zeiss, Oberkochen, Germany), or OCT-HS100 system (Canon, Tokyo, Japan). Foveal enhanced-depth imaging OCT scan was acquired (Spectralis). Fundus autofluorescence images, fluorescein, and indocyanine green (ICG) angiography (ICGA) were acquired with the Spectralis, OCT-HS100, or TRC fundus camera (Topcon, Tokyo, Japan).
The cases were reviewed by two retina specialists (F.B.-C., R.F.S.) to identify features related to CSC or MacTel Type 2. Presence of choroidal vasodilation was assessed qualitatively on the best-available OCT scans visualizing the choroidal vasculature.
Subfoveal choroidal thickness was measured on horizontal foveal enhanced-depth imaging -OCT scans by one observer (A.M.). When enhanced-depth imaging-OCT was not available, OCT image contrast was enhanced using Photoshop cc (2017.0.1; Adobe Systems Inc, San Jose, CA) to reveal the outer choroid/sclera interface.
Descriptive and contingency statistics were performed on GraphPad Prism (version 5.0f; GraphPad Software, La Jolla, CA). 
Results
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Clinical Characteristics
The mean LogMAR visual acuity was 0.60, corresponding to 20/33 (20/160-20/20) . Four patients (Cases 1-3, 5) were referred for chronic or nonresolving CSC, and an additional diagnosis of MacTel Type 2 was made at the tertiary center. One patient was followed for advanced MacTel Type 2 (Case 4), and experienced acute CSC detected during a routine visit. Table 1 summarizes their medical and ocular history. Two patients had Type 2 diabetes mellitus, and one had severe heart disease. One patient reported corticosteroid use.
Multimodal imaging findings diagnostic of MacTel Type 2 and CSC are reported in Table 2 , and Figures 1-5 provide a case-by-case illustration. Two patients had bilateral MacTel Type 2 findings and two had bilateral CSC. All affected eyes shared manifestations of both diseases, except Case 4 who had mostly CSC features in his right eye, and MacTel Type 2 features in his left eye. In total, six eyes presented features of both disorders, two eyes presented MacTel Type 2 findings only (Cases 1 and 4, left eye), and two eyes presented CSC findings only (Cases 4 and 5, right eye). One eye showed granular changes in the pigmentation at the level of the retinal pigment epithelium suggestive of past fluid (Case 2, left eye).
CSC Features
Regarding the diagnosis of CSC, four patients (five eyes) exhibited subretinal fluid, and three patients (five eyes) presented one or several pigment epithelial detachments. Fundus autofluorescence alterations from long-standing serous detachments were found in four patients (seven eyes). Active fluorescein leakage was detected in two cases (three eyes), but focal or extended retinal pigment epithelium alterations was present in all five patients (nine eyes). Indocyanine green angiography was performed in four patients, all showing choroidal vascular hyperpermeability (eight eyes), including two contralateral eyes with MacTel Type 2 features but no signs of past CSC episodes (Cases 1 and 4, left eye), and 1 eye with thick choroid (490 mm) without CSC (Case 2, left eye). Mean subfoveal choroidal thickness of all 10 eyes was 402 ± 99 mm (210-577 mm), and was 424 ± 87 mm (313-577 mm) when considering only the 6 eyes with combined MacTel Type 2 and CSC. Of the 5 patients, 4 had a subfoveal choroidal thickness $395 mm in at least 1 eye, a previously recognized threshold for pachychoroid. 16 In all eyes, dilated large choroidal vessels could be qualitatively discerned on OCT. One patient (Case 2) presented pattern-like peripapillary yellowish subretinal deposits in both eyes, best visible on fundus autofluorescence.
MacTel Type 2 Features
Regarding MacTel Type 2 features, a focal loss of transparency temporal to the fovea was visible with ophthalmoscopy in all five patients (nine eyes), and a perifoveal hyperfluorescence found on fundus autofluorescence was present in four patients (seven eyes).
In two patients (Case 1, right eye and Case 5, both eyes), perifoveal fundus autofluorescence could not be evaluated because of a large area of retinal pigment epithelium alteration resulting from chronic CSC. Four subjects presented pigment clumps or crystal deposits. Leaky perifoveal telangiectasia were visible in early and late-phase Fundus autofluorescence in all five subjects (seven eyes with patent MacTel Type 2). Four cases (five eyes) had intraretinal cavitations with typical MacTel Type 2 morphology on OCT, including loss of retinal tissue without retinal thickening, and square edges. When the cavitations were located in the A 78-year-old man with MacTel Type 2 and CSC in the right eye. The patient had recurrent subretinal fluid and peripapillary intraretinal cystoid spaces that seemed unresponsive to intravitreal aflibercept. At presentation, crystal deposits were visible temporal to the fovea (A, white arrow), and both fundus exhibited pattern-like peripapillary yellowish subretinal deposits (A and G, yellow arrows), best visualized on green-light fundus autofluorescence (B and H, yellow arrows). Perifoveal loss of retinal transparency was visible in the right fundus (A, purple arrow). Fluorescein angiography showed subtle leakage and staining from perifoveal telangiectasia in the right eye (C, white arrow), and in both eyes a peripapillary window defect (C and I, green arrows). ICGA showed bilateral choroidal vessel dilation and hyperpermeability (D and J, blue arrows). An OCT scan superior to the fovea identified peripapillary subretinal fluid and schisis-like intraretinal cystoid spaces (E, pink and white arrows). A foveal OCT scan identified square-shaped inner atrophic cavitations typical of MacTel Type 2 (F, orange arrow), and an outer retinal cavity with interrupted ellipsoid zone, fused with the subfoveal detachment (F, yellow arrow). OCT showed bilaterally a thick choroid, with enlarged vessels (E and K, blue arrows). The left eye did not show signs of MacTel Type 2. Multimodal findings did not identify differential diagnoses for peripapillary intraretinal edema, such as polypoidal choroidal vasculopathy, optic disc pit, glaucoma or hypertensive retinopathy.
inner retina, their inner retinal border was the inner limiting membrane (Cases 2 and 3, right eye; Case 5, left eye). Cases also showed focal or extended interruptions of the ellipsoid zone (Cases 1, 2 and 5), and presence of a large hyperreflective lesion (Cases 4 and 5, left eye). OCT exhibited typical cavitations with disruption of the normal retinal lamination and loss of the ellipsoid zone in the right eye (G and H, orange arrows), and one smaller cavitation in the left eye (P, orange arrow). CSC manifested with peripapillary and macular serous detachments in the right (G) and left eye (O), associated with focal pigment epithelial detachments (G and O, pink arrow). Both eyes showed granular autofluorescence changes (B and J), and extended window defects on fluorescein angiography at 1 (C and K) and 6 minutes (D and L) (green arrows) with a leakage site in the right eye (C and D, pink arrow). ICGA demonstrated bilateral choroidal vessel dilation (E and M) and hyperpermeability (F and N). After nonresolving subretinal detachment for more than 6 months, photodynamic therapy was performed followed by reattachment in both eyes (H and P), but subretinal fluid recurred 9 months later.
Natural History and Treatment
Serous retinal detachments were detected in five eyes (four patients), three of whom had a foveal detachment. The natural evolution of subretinal fluid, and response to therapy was variable. It resolved spontaneously in two eyes, 1 and 3 months after detection (Cases 4 and 2, right eye, respectively), persisted for 6 and 8 months and then resolved after photodynamic therapy in two eyes (Case 3, right and left eye, respectively), and persisted despite oral mineralocorticoid-receptor antagonist therapy (spironolactone 50 mg/day) in 1 eye (Case 1, right eye).
Discussion
This study reports the cooccurrence of clinical manifestations from both MacTel Type 2 and CSC in five patients seen in four different tertiary retinal centers, During routine evaluation, a subretinal detachment was detected in her right eye that resolved spontaneously over 1 month, and was attributed to CSC. The MacTel Type 2 findings were: perifoveal opacification (A and H, yellow arrow) and pigment clumping (H, white arrow), focal hyperautofluorescence (B and I, yellow arrow) and fluorescein leakage temporal to the fovea (J and K, white arrow). The pigment clumping produced a masking effect on ICGA (L and M, yellow arrow), that showed no signs of neovascularization. OCT showed a hyperreflective lesion temporal to the fovea corresponding to outer retinal pigment migration (N, pink arrow) with focal disorganization of retinal layers (N, orange arrow). There were early MacTel Type 2 signs in the right eye with perifoveal focal retinal opacification (A, yellow arrow), hyperautofluorescence (B, yellow arrow) and telangiectasia without leakage (C and D, white arrow). Central serous chorioretinopathy manifested with a serous detachment superonasal to the macula (G, green arrow). At the same location, fluorescein angiography showed a focal window defect (C and D, green arrow) and ICGA showed enlarged choroidal vessels and hyperpermeability at 1 and 10 minutes (E and F, blue arrow). Similar findings on ICGA were visible in the unaffected left eye (L and M, blue arrow).
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supported by their multimodal imaging findings, and their spontaneous evolution or treatment response. Four of them had chronic CSC and were additionally diagnosed with MacTel Type 2, while one case had MacTel Type 2 and experienced an acute CSC episode.
Note, that patients with MacTel Type 2 and increased choroidal thickness in the absence of subretinal fluid were not considered since the prevalence of increased choroidal thickness in the general population and its exact influence on the risk of CSC are not known. Whether MacTel Type 2 patients have increased choroidal thickness is controversial. While Chhablani et al 49 did not observe any significant difference in the choroidal thickness of 41 MacTel Type 2 patients from India as compared to sex-and agematched controls, Nunes et al 50 found the mean choroidal thickness to be 41 mm greater in a cohort of 62 MacTel Type 2 patients in the United States (of whom 40% were diabetic) than a group of sex-and agematched controls. However, only 15 of the MacTel Type 2 eyes (24%) had a subfoveal choroidal thickness greater than 400 mm. Several underlying factors may explain the variability of choroidal thickness observed in these MacTel Type 2 patients, including ethnicity 15, 16 and diabetes, 51 although the exact influence of these factors on choroidal thickness is still debated. [52] [53] [54] Previous observations have reported foveal detachments in MacTel Type 2 eyes. In 25 eyes with MacTel Type 2, Gaudric et al 55 identified 2 eyes with foveal detachment without subretinal neovascularization. Recently, among 427 cases from 3 sites contributing to the international MacTel Type 2 Project, 6 cases (1.4%) presented with subretinal fluid causing foveal detachment, a proportion similar to the rate of CSC observed among MacTel cases in the present study. 56 Four cases showed fluctuation in the amount of subretinal fluid, with spontaneous resolution in three cases, and partial resolution followed by recurrence in one case, that ultimately responded to intravitreal anti-VEGF. The last two cases responded to intravitreal anti-VEGF, and a neovascular lesion was suspected. Consistently, leakage from deep vascular invasion and subretinal neovascularization in MacTel Type 2 does respond to anti-VEGF agents. 57, 58 Indocyanine green angiography was not systematically performed, yet authors ruled out the possibility of leakage from the choroid as observed in CSC, based on fundus autofluorescence findings. Cases from the present series did not appear to have vascular proliferation with leakage and had findings consistent with CSC.
The cooccurrence reported in this study may be coincidental, or may result from an overlap between pathophysiological processes underlying CSC and MacTel Type 2. One possible hypothesis is that similar systemic factors could increase the risk of both disorders, such as diabetes mellitus. The medical records of the five patients reported in Table 1 did not show common factors among all the patients. Another possibility is that MacTel Type 2 may require the combination of a genetic predisposition and suitable second triggers to develop manifest disease, either systemic, such as mild diabetes or metabolic syndrome, 38 or local, such as irradiation 59 or changes induced by other ocular conditions. This report had several limitations. The limited number of cases recruited in tertiary retinal centers, reflects the rarity of the reported cooccurrence. As such, this investigation seeks to gain clues to the potential implications of this cooccurrence, and not to estimate its actual frequency. The joint probability for a given individual to develop MacTel Type 2 and CSC would be very difficult to determine given that MacTel Type 2, 60 and forms of extramacular, asymptomatic CSC are often underdiagnosed, and that variable prevalence of MacTel Type 2 [60] [61] [62] [63] and CSC [64] [65] [66] have been reported in the literature. The MacTel-specific incidence of CSC, or inversely the CSC-specific incidence of MacTel Type 2 could be estimated by natural history studies, but long-term follow-up of very large cohorts would be required.
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